Galectin-3 and outcomes after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention.

Abstract

AIM:

Galectin-3 (Gal-3), a biomarker of inflammation, tissue repair and fibrogenesis, is associated to left ventricular remodeling after ST-elevated myocardial infarction (STEMI), but its relation with long-term outcomes is unclear.

METHODS:

In 103 consecutive patients with a first anterior STEMI treated by primary angioplasty, we assayed Gal-3 and NT-proBNP.

RESULTS:

Age was 65 (56-76) years, 28% were women. During 18 ± 13 months, 20 patients (19.4%) died or were admitted for heart failure. After adjustment for age, gender, renal and ventricular function, troponin, NT-proBNP and Gal-3 independently predicted the combined end point (hazard ratio: 1.11; 95% CI: 1.05-1.17; per 1 ng/ml increase). Event-free survival was 42.3 versus 93.5% for Gal-3≥ versus <16.8 ng/ml (p < 0.001).

CONCLUSION:

Among anterior STEMI patients, early postangioplasty Gal-3 levels may be useful for risk stratification.

• Authors: Giuseppe Di Tano, Giorgio Caretta, Renata De Maria, Luca Bettari, Marina Parolini, Sophie Testa, Salvatore Pirelli
• Journal: Biomarkers in medicine (Biomark Med) Vol. 12 Issue 1 Pg. 21-26 (Jan 2018) ISSN: 1752-0371 [Electronic] England
• PMID: 29243525 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• Blood Proteins
• Galectin 3
• Galectins
• LGALS3 protein, human

Topics

• Aged
• Biomarkers (metabolism)
• Blood Proteins
• Female
• Galectin 3 (genetics, metabolism)
• Galectins
• Heart Failure (genetics, metabolism, pathology, surgery)
• Humans
• Male
• Middle Aged
• Myocardial Infarction (genetics, metabolism, pathology, surgery)
• Percutaneous Coronary Intervention
• Prognosis